TARA Q3 FY2026 earnings: results, stock reaction and implied move

Reported results

Net loss for the third quarter of 2026 was $21.7 million, or $0.35 per basic and diluted share, compared with a net loss of $13.3 million, or $0.31 per share, for the prior-year period.
Research and development expenses for the third quarter of 2026 were $16.8 million, compared to $9.6 million for the prior year period.
General and administrative expenses for the third quarter of 2026 were $6.3 million, compared to $5.2 million for the prior-year period.
Unrestricted cash and cash equivalents and marketable debt securities totaled $143.1 million as of September 30, 2026.
Protara entered into an asset purchase agreement on November 4, 2026, for TARA-002 manufacturing-related assets for an aggregate purchase price of $8.75 million.

The Company expects its cash and cash equivalents and marketable debt securities will be sufficient to fund its planned operations and milestones into 2028.
The Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in the fourth quarter of 2026.
The Company expects to complete enrollment in the STARBORN-1 trial early in the first quarter of 2027.
The Company expects to initiate a rolling BLA submission for TARA-002 in the second half of 2027.
The Company remains on track to report interim results from the Phase 2b portion of THRIVE-3 in the fourth quarter of 2026.

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.